Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis

Thrombosis and Haemostasis

Volumn 105, Issue 1, 2011, Pages 181-189

  Barrett, Yu Chen ^a   Wang, Jessie ^a   Knabb, Robert ^a   Mohan, Puneet ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Apixaban; Biomarkers; Blood coagulation; Deep vein thrombosis; Direct factor Xa inhibitor; Oral anticoagulant

Indexed keywords

ACENOCOUMAROL; APIXABAN; D DIMER; ENOXAPARIN; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TINZAPARIN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REFERENCE VALUE; THROMBIN TIME; TREATMENT DURATION;

ANTICOAGULANTS; BIOLOGICAL MARKERS; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PYRAZOLES; PYRIDONES; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 78651098985     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-06-0393     Document Type: Article

References (14)

1. Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003; 349: 1227-1235.
2. Breddin HK, Kadziola Z, Scully M, et al. Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis. Thromb Haemost 2003; 89: 272-277.
3. Sadanaga T, Sadanaga M, Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol 2010; 55: 2225-2231.
4. Palareti G, Legnani C, Cosmi B, et al. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002; 87: 7-12.
5. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780-1789.
6. Cosmi B, Legnani C, Tosetto A, et al. Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood 2010; 115: 481-488.
7. Kakkar VV, Hoppenstead DA, Fareed J, et al. Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. Blood 2002; 99: 1965-1970. (Pubitemid 34525476)
8. Christersson C, Oldgren J, Bylock A, et al. Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial. Eur Heart J 2007; 28: 692-698. (Pubitemid 46439238)
9. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008; 6: 820-829.
10. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5: 2368-2375.
11. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
12. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-815.
13. Buller H, Deitchman D, Prins M, et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6: 1313-1318.
14. Barrett YC, Wang J, Yu Z, et al. Apixaban treatment decreases coagulation activity in patients with acute deep-vein thrombosis. Presented at the 50th Annual Meeting of the American Society for Hematology, December 6-9, 2008; San Francisco, CA, USA.